News
Clinical Trials Arena on MSN17h
SynOx completes enrolment in Phase III trial of emactuzumab for TGCTSynOx Therapeutics has completed subject enrolment in its multi-centre Phase III TANGENT trial of the humanised IgG1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback